Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Key Points

• Traders bought 4,063 put options on Xenon (XENE) Wednesday — a 2,362% increase over the average of 165 puts, marking unusually heavy options activity and potential bearish positioning or hedging.
• Significant insider selling occurred on March 10 (Christopher Kenney sold 2,771 shares; Andrea Difabio sold 2,607), and insiders have offloaded 336,707 shares worth about $19.6M over the past 90 days, leaving insiders with 4.07% ownership.
• Analysts remain broadly positive with a consensus "Buy" and a $71.88 target (price targets up to $97 from some firms); the stock trades around $56.69 and has a 12‑month range of $26.74–$63.95.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average volume of 165 put options.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $56.69 on Thursday. The stock has a market capitalization of $4.72 billion, a P/E ratio of -13.00 and a beta of 0.91. The business has a 50 day simple moving average of $47.39 and a two-hundred day simple moving average of $43.49. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the business earned ($0.84) earnings per share. As a group, research analysts anticipate that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an "outperform" rating and a $60.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a research report on Friday, January 9th. Guggenheim reissued a "buy" rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. HC Wainwright raised their target price on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a "buy" rating in a research report on Tuesday, March 10th. Finally, Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $71.88.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 2,771 shares of the company's stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $166,564.81. Following the sale, the insider owned 4,729 shares in the company, valued at approximately $284,260.19. This represents a 36.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Andrea Difabio sold 2,607 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the sale, the insider directly owned 4,893 shares in the company, valued at $294,118.23. The trade was a 34.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 336,707 shares of company stock worth $19,622,565. 4.07% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently modified their holdings of XENE. Elevation Point Wealth Partners LLC purchased a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $32,000. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at about $32,000. Blue Trust Inc. grew its stake in Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 717 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in Xenon Pharmaceuticals in the 4th quarter valued at about $33,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in Xenon Pharmaceuticals in the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.